Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Master rollover study of trastuzumab deruxtecan for long-term access and safety
2023-506330-73-00Phase 3Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of trastuzumab deruxtecan in Nonhematologic neoplasms, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Treatment-emergent adverse events leading to study drug discontinuation and/or dose reduction, Treatment-emergent serious adverse events (TESAEs) and 1 more. Planned start Feb 2024; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-506330-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506330-73-00.